Vertex, Inc. (NASDAQ: VERX) announced that it will release its financial results for the third quarter of 2025 before the market opens on Monday, November ...
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares.
Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
Abstract: The quadratic Lyapunov function-based method for consensus analysis of discrete-time single-integrator multiagent systems (MASs) in general time-varying directed networks is not well ...
Abstract: In this article, we develop a systematic method for constructing a generalized discrete-time control Lyapunov function for the flexible-step model predictive control (MPC) scheme, recently ...
Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around 75,000 people with cystic fibrosis rely on Vertex Pharmaceuticals to keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results